At close: December 13 at 4:00:02 PM EST
After hours: 7:29:13 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
104,750.0000
76,533.0000
96,631.0000
99,535.0000
135,292.0000
Operating Income
-104,750.0000
-76,533.0000
-96,631.0000
-99,535.0000
-135,292.0000
Net Non Operating Interest Income Expense
2,603.0000
3,714.0000
427.0000
425.0000
-724.0000
Other Income Expense
--
--
--
920.0000
-23,552.0000
Pretax Income
-102,047.0000
-72,719.0000
-96,204.0000
-98,189.0000
-159,566.0000
Tax Provision
42.0000
7.0000
70.0000
-381.0000
-10.0000
Net Income Common Stockholders
-102,089.0000
-72,726.0000
-96,274.0000
-97,809.0000
-159,555.0000
Diluted NI Available to Com Stockholders
-102,089.0000
-72,726.0000
-96,274.0000
-97,809.0000
-159,555.0000
Basic EPS
-1.06
-0.76
-1.24
-1.78
-2.95
Diluted EPS
-1.06
-0.76
-1.24
-1.78
-2.95
Basic Average Shares
96,161.1140
95,121.3900
77,661.2900
54,948.8760
54,092.6660
Diluted Average Shares
96,161.1140
95,121.3900
77,661.2900
54,948.8760
54,092.6660
Total Operating Income as Reported
-104,648.0000
-76,432.0000
-96,631.0000
-98,614.0000
-158,842.0000
Rent Expense Supplemental
--
--
--
--
1,064.0000
Total Expenses
104,750.0000
76,533.0000
96,631.0000
99,535.0000
135,292.0000
Net Income from Continuing & Discontinued Operation
-102,089.0000
-72,726.0000
-96,274.0000
-97,809.0000
-159,555.0000
Normalized Income
-102,089.0000
-72,726.0000
-96,274.0000
-98,725.4120
-136,004.4760
Interest Expense
--
--
--
--
724.0000
Net Interest Income
2,603.0000
3,714.0000
427.0000
425.0000
-724.0000
EBIT
-104,750.0000
-76,533.0000
-96,631.0000
-99,535.0000
-135,292.0000
EBITDA
-96,591.0000
-67,372.0000
-83,469.0000
-86,316.0000
-122,800.0000
Reconciled Depreciation
-12,489.0000
-13,998.0000
13,162.0000
8,376.0000
10,461.0000
Net Income from Continuing Operation Net Minority Interest
-102,089.0000
-72,726.0000
-96,274.0000
-97,809.0000
-159,555.0000
Total Unusual Items Excluding Goodwill
--
--
--
920.0000
-23,552.0000
Total Unusual Items
--
--
--
920.0000
-23,552.0000
Normalized EBITDA
-96,591.0000
-67,372.0000
-83,469.0000
-87,236.0000
-99,248.0000
Tax Rate for Calcs
0.0003
0.0000
0.0000
0.0000
0.0000
Tax Effect of Unusual Items
--
--
--
3.5880
-1.4760
12/31/2020 - 10/22/2014
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
PALI Palisade Bio, Inc.
1.7700
-25.00%
TRVI Trevi Therapeutics, Inc.
4.1700
+15.83%
IPHA Innate Pharma S.A.
3.0200
+96.10%
THAR Tharimmune, Inc.
2.1400
-1.83%
SLXN Silexion Therapeutics Corp
3.5200
+5.39%
DRMA Dermata Therapeutics, Inc.
1.0900
0.00%
PBM Psyence Biomedical Ltd.
1.8500
-9.31%
PCSA Processa Pharmaceuticals, Inc.
1.1100
-11.20%
SONN Sonnet BioTherapeutics Holdings, Inc.
1.8100
+2.26%
NBTX Nanobiotix S.A.
3.3300
+1.52%